免疫|免疫＋抗血管靶向药物，这样的联合方案在哪些癌种治疗效果好？( 三 )
讨论
ICIs＋抗血管生成药物联合治疗方案取得的疗效明显优于单药治疗，尤其在挑战难治性肿瘤、患者化疗不耐受/抗拒化疗等情形下取得优异疗效，由此提供了一种去化疗的优质可选方案 。
参考文献
1Di Huang, Pengfei Cui, Ziwei Huang, et al. AntiPD1/L1 plus antiangiogenesis therapy as secondline or later treatment in advanced lung adenocarcinoma[J]. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-020-03380-x.
2Qiu L, Zhao X, Shi W, et al. Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients[J]. Medicine 2020;99:24(e20545).
3Shengjie Yang, Wenjie Zhang, Qing Chen, et al. Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study[J]. Cancer Management and Research 2020:12 10333–10340.
4Guosheng Yuan, Xiao Cheng, Qi Li, et al. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study[J]. OncoTargets and Therapy 2020:13 12683–12693.
5Jieqiong Liu, Qiang Liu, Ying Li, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an openlabel phase II trial[J]. J Immunother Cancer 2020;8:e000696. doi:10.1136/jitc-2020-000696.
6Joyce F. Liu, Christina Herold, Kathryn P. Gray, et al. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial[J]. JAMA Oncology, 2019, doi:10.1001/jamaoncol.2019.3343.
推荐阅读
- 脚趾|男子抽烟20年致血管堵塞，三个脚趾坏死保不住了
- 滤泡性淋巴瘤|滤泡性淋巴瘤患者新希望！广东首张奥妥珠单抗药物处方落地
- 遗传|从“母亲”那遗传来的抗压能力，算不算外挂？
- 人类免疫缺陷病毒|深港团队开发艾滋病新抗体：动物实验中能100％预防HIV
- 血管|睡醒后若有3种迹象，血管已经“受损”，哪怕占一个，也要尽早检查
- 高血脂|常吃2种天然食物，血管被“洗”干净，高血脂、血管斑块也怕你
- 苔丝·安德拉德|丈夫感染新冠住进ICU，妻子却没事，有人天生对新冠免疫？
- 程意|我27岁，抗癌10个月，这是我患癌的前兆……
- 肿瘤|突破：抗癌疗法可“杀死”多种癌症，副作用少，已有患者肿瘤消失
- 好消息：新抗癌疗法“杀死”多种癌症，副作用少，有患者肿瘤消失